Group 1 - Pfizer's stock has declined by 25% over the past five years, while the S&P 500 has increased by 68%, leading to a loss of investor confidence in the company's growth potential [1] - The stock has recently started to outperform the S&P 500, attributed to increased market concerns and a shift towards dividend stocks, with Pfizer's dividend yield at 6.4% [2][5] - In 2023, Pfizer's stock experienced a significant drop of 44%, and it has faced declines in previous years, including a 6% drop in 2025 and an 8% drop in 2024 [4] Group 2 - Despite a modest gain of 8% this year, Pfizer's stock remains undervalued with a forward price-to-earnings multiple of just over nine [6] - The company's revenue for the past year was $62.6 billion, reflecting a 2% operational decline from the previous year, indicating stability despite growth concerns [7]

Core Insights - Pfizer Inc has secured a three-year grace period from tariffs on pharmaceuticals promised by President Donald Trump, which is expected to lower some of the company's drug prices in the US [1] - The company will offer certain drugs at an average discount of 50% through a direct-to-consumer website named TrumpRx, aimed at providing Americans with access to discounted prescription prices negotiated by the government [1]